Anixa Biosciences Inc (ANIX) stock
ANIXNasdaqPharmaceutical PreparationsFiscal year ends October 31
$2.67+0.12 (+4.71%)
Close on Nov 17, 2026Market cap $92.82MP/E –Yield –
Anixa Biosciences r&d expenses
Research and development expenses are spending on new products and technology.
Anixa Biosciences's R&D Expenses for the twelve months ending Jul 31, 2026 was $4.83M, down 10.7% year over year. For fiscal 2025 it was $5.07M, down 20.7% from the year before. Over ten years it grew 21.7% a year on average. The highest annual figure on record is $6.81M in fiscal 2018.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | $5.07M | -20.7% |
| FY2024 | Oct 31, 2024 | $6.40M | +34.1% |
| FY2023 | Oct 31, 2023 | $4.77M | -28.9% |
| FY2022 | Oct 31, 2022 | $6.70M | +8.3% |
| FY2021 | Oct 31, 2021 | $6.19M | +41.3% |
| FY2020 | Oct 31, 2020 | $4.38M | -20.0% |
| FY2019 | Oct 31, 2019 | $5.47M | -19.7% |
| FY2018 | Oct 31, 2018 | $6.81M | +326.5% |
| FY2017 | Oct 31, 2017 | $1.60M | +2.6% |
| FY2016 | Oct 31, 2016 | $1.56M | +118.8% |
| FY2015 | Oct 31, 2015 | $711.39K | -67.8% |
| FY2012 | Oct 31, 2012 | $2.21M | -29.2% |
| FY2011 | Oct 31, 2011 | $3.12M | +3.9% |
| FY2010 | Oct 31, 2010 | $3.01M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jul 31, 2026 | $1.33M | +25.7% |
| Q2 FY2026CQ1 2026 | Apr 30, 2026 | $1.26M | -4.8% |
| Q1 FY2026CQ4 2025 | Jan 31, 2026 | $1.10M | -29.0% |
| Q4 FY2025CQ3 2025 | Oct 31, 2025 | $1.14M | -22.6% |
| Q3 FY2025CQ2 2025 | Jul 31, 2025 | $1.06M | -45.2% |
| Q2 FY2025CQ1 2025 | Apr 30, 2025 | $1.32M | -19.7% |
| Q1 FY2025CQ4 2024 | Jan 31, 2025 | $1.55M | +15.0% |
| Q4 FY2024CQ3 2024 | Oct 31, 2024 | $1.48M | -8.6% |
| Q3 FY2024CQ2 2024 | Jul 31, 2024 | $1.93M | +76.9% |
| Q2 FY2024CQ1 2024 | Apr 30, 2024 | $1.65M | +64.9% |
| Q1 FY2024CQ4 2023 | Jan 31, 2024 | $1.35M | +26.3% |
| Q4 FY2023CQ3 2023 | Oct 31, 2023 | $1.62M | -4.2% |
| Q3 FY2023CQ2 2023 | Jul 31, 2023 | $1.09M | -24.7% |
| Q2 FY2023CQ1 2023 | Apr 30, 2023 | $998.00K | -42.5% |
| Q1 FY2023CQ4 2022 | Jan 31, 2023 | $1.07M | -41.9% |
| Q4 FY2022CQ3 2022 | Oct 31, 2022 | $1.69M | -22.5% |
| Q3 FY2022CQ2 2022 | Jul 31, 2022 | $1.45M | -33.3% |
| Q2 FY2022CQ1 2022 | Apr 30, 2022 | $1.74M | +69.8% |
| Q1 FY2022CQ4 2021 | Jan 31, 2022 | $1.84M | +122.0% |
| Q4 FY2021CQ3 2021 | Oct 31, 2021 | $2.17M | +433.0% |
| Q3 FY2021CQ2 2021 | Jul 31, 2021 | $2.17M | +72.8% |
| Q2 FY2021CQ1 2021 | Apr 30, 2021 | $1.02M | -16.8% |
| Q1 FY2021CQ4 2020 | Jan 31, 2021 | $828.00K | -44.5% |
| Q4 FY2020CQ3 2020 | Oct 31, 2020 | $407.70K | -53.2% |
| Q3 FY2020CQ2 2020 | Jul 31, 2020 | $1.25M | +15.5% |
| Q2 FY2020CQ1 2020 | Apr 30, 2020 | $1.23M | -3.2% |
| Q1 FY2020CQ4 2019 | Jan 31, 2020 | $1.49M | -33.7% |
| Q4 FY2019CQ3 2019 | Oct 31, 2019 | $871.19K | -64.2% |
| Q3 FY2019CQ2 2019 | Jul 31, 2019 | $1.09M | -63.1% |
| Q2 FY2019CQ1 2019 | Apr 30, 2019 | $1.27M | +92.3% |
| Q1 FY2019CQ4 2018 | Jan 31, 2019 | $2.25M | +188.9% |
| Q4 FY2018CQ3 2018 | Oct 31, 2018 | $2.43M | +591.5% |
| Q3 FY2018CQ2 2018 | Jul 31, 2018 | $2.94M | +710.6% |
| Q2 FY2018CQ1 2018 | Apr 30, 2018 | $660.19K | +53.1% |
| Q1 FY2018CQ4 2017 | Jan 31, 2018 | $777.87K | +72.2% |
| Q4 FY2017CQ3 2017 | Oct 31, 2017 | $351.83K | -14.9% |
| Q3 FY2017CQ2 2017 | Jul 31, 2017 | $362.97K | – |
| Q2 FY2017CQ1 2017 | Apr 30, 2017 | $431.12K | – |
| Q1 FY2017CQ4 2016 | Jan 31, 2017 | $451.63K | – |
| Q4 FY2016CQ3 2016 | Oct 31, 2016 | $413.49K | – |
See a number that looks wrong?